Path 7.5mg Tablet

icon
Lupin Ltd

Composition for Path 7.5mg Tablet

iconPrescription Required

Primarily used for

Potentiallyunsafewith
icon
Alcohol
71.25
₹4.75/Tablet
15 tablets in 1 strip
ADD TO CART

Medicine Overview of Path Tablet

uses

Uses of Path Tablet

Path 7.5mg Tablet is used in the treatment of type 2 diabetes.
uses

Side effects of Path Tablet

Common

Blurred vision, Respiratory tract infection, Bone fracture, Numbness.

uses

How to use Path Tablet

Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. It can be taken with or without food, but it is better to take Path 7.5mg Tablet at a fixed time.

How Path Tablet works

Path 7.5mg tablet is an anti-diabetic medication. It works by increasing the body's sensitivity to insulin, a natural substance that helps control blood sugar levels.

In Depth Information on Path Tablet

Expert advice for Path Tablet

  • Highly effective in decreasing haemoglobin A1c level (Hemoglobin A1c measures average blood sugar over time).
  • Path may rarely cause hypoglycemia.
  • Path is more likely to cause weight gain as compared to other anti-diabetic medicines.
  • Path may cause fluid retention (edema), ranging from mild ankle swelling to severe swelling in the lungs that make it hard to breathe.
  • Inform your doctor if you have ever been diagnosed with any heart problems (high blood pressure, heart attack, heart failure, slow or irregular heart rate).
  • Inform your doctor if you have ever been diagnosed with kidney or liver problems.
  • Inform your doctor if you have ever been diagnosed with bladder cancer.
video imgplay img
Warnings
Special precautions for Path 7.5mg Tablet
icon
Alcohol
CAUTION
Taking pioglitazone with alcohol may affect blood glucose levels in patients with diabetes.
icon
Pregnancy
WEIGH RISKS VS BENEFITS
Path 7.5mg Tablet may be unsafe to use during pregnancy.

Animal studies have shown adverse effects on the foetus, however, there are limited human studies. The benefits from use in pregnant women may be acceptable despite the risk. Please consult your doctor.
...
+more
icon
Lactation
Path 7.5mg Tablet is probably safe to use during lactation. Limited human data suggests that the drug does not represent a significant risk to the baby.

Monitor the breastfed baby’s blood sugar during treatment with Path 7.5mg Tablet
...
+more
icon
Driving
SAFE
Path 7.5mg Tablet does not usually affect your ability to drive.
icon
Kidney
SAFE
Path 7.5mg Tablet is safe to use in patients with kidney disease. No dose adjustment of Path 7.5mg Tablet is recommended.

Use of Path 7.5mg Tablet is not recommended in patients undergoing dialysis.
...
+more
icon
Liver
CAUTION
Path 7.5mg Tablet should be used with caution in patients with liver disease. Dose adjustment of Path 7.5mg Tablet may be needed. Please consult your doctor.

Use of Path 7.5mg Tablet is not recommended in patients with severe liver disease.
...
+more
Severely interacts with other drugs like
Apidra 100IU Cartridge 3ml, Decamycin 4mg Injection, Manoprolol 40mg Tablet, Betsone 0.5mg Tablet

Missed Dosageuses

If you miss a dose of Pioglitazone, skip it and continue with your normal schedule. Do not double the dose.

Patient Concerns

Frequently asked questions for Path 7.5mg Tablet

Frequently asked questions for Pioglitazone

No. Path is an anti-diabetic medication. Blood thinners are the medicine that prevents the formation of a harmful blood clot. These include medicines like Aspirin, Heparin and Warfarin.
Q. Is Path a diuretic?
No. Path is not a diuretic. It is used in the treatment of Diabetes Mellitus. Diuretics are those medicine which increases urination.
Q. Can Path used in Hepatitis B infection?
Some studies have shown that Path may be helpful in preventing Hepatitis B Virus-associated Hepatocellular Cancer (Liver Cancer). However, these findings are still very preliminary and clear role has not been established.
Path has been shown to inhibit Liver Cancer (HCC) recurrence in overweight Hepatitis C Virus-infected diabetic patients. It also improved insulin resistance (a state where the body is resistant to the effects and functions of the insulin hormone) in them.
Q. Can Path used along with Vitamin D?
Studies indicate that Vitamin-D combined with Path may be more effective in improving Bone Mineral Density and Bone Metabolism than Vitamin-D or Path alone in the treatment of Diabetes Mellitus patients with kidney dysfunction (Diabetic Nephropathy).
Q. Can Path be used along with sitagliptin?
Combination therapy with Sitagliptin and Path leads to a substantial and sustained improvement in glycemic (blood sugar) control compared to the treatment with Path alone. This is useful for patients who cannot tolerate Metformin or Sulfonylureas.
Recent evidence suggests that Path may be beneficial in Alzheimer's disease (AD), decreasing the cognitive decline early in the disease process. However, larger studies are now in progress to establish the same.
Q. Can Path and repaglinide combined in diabetes treatment?
For patients who previously failed oral antidiabetic therapy, the combination of Repaglinide and Path have acceptable safety, with greater reductions of glycemic parameters (blood sugar levels) than using either agent alone.
Large population studies indicate that Path is associated with an increased risk of bladder cancer. The absence of an association of bladder cancer with the other drug of the same class, Rosiglitazone, suggests that the increased risk is drug specific and not a class effect.
Q. Are Path and rosiglitazone same?
Path & Rosiglitazone both belong to a class of antidiabetics called Thiazolidinediones. Rosiglitazone has been removed from the market because using this drug was associated with increased risk of cardiovascular events like heart attack and stroke. This is not seen with Path.
Q. Can Path be used along with glimepiride in diabetes?
Path when added to Glimepiride in Patients with Diabetes Mellitus, has been found to significantly reduce plasma lipid levels and significant improvement in blood pressure control related to a reduction in the insulin resistance.
No. Path is not a steroid. It is an anti-diabetic medication which belongs to the class of thiazolidinediones.
Path is an anti-diabetes drug used along with a proper diet and exercise program to control high blood sugar in patients with type 2 diabetes. Path acts as an insulin sensitizer and decreases the extent of insulin resistance in the body too.
Path cardiovascular safety profile compares favourably with that of Rosiglitazone. Path has been found to be associated with bladder tumours but causality assessment has not been proved yet.
Path increases the permeability of fluid in tiny blood vessels called capillaries. This results in easier movement of fluids across the membrane and their consequent accumulation, resulting in oedema (puffiness). Also, Path causes increased sodium and water reabsorption from the kidney that contributes to the oedema.
The mechanism behind the link between Path use and bladder cancer is still unknown. Studies have suggested that use of Path for more than one year results in increased risk of development of tumour of the urinary bladder.
Path can cause fluid retention and edema. Consequently, there is a lot of fluid in the body (fluid overload). As a result, it may precipitate heart failure (which worsens with fluid overload in those at risk).
Studies in animals have concluded that Path improves the elasticity of the aortic wall ( the aorta is a large blood vessel that arises from the heart and supplies oxygenated blood to the rest of the body). This may be a mechanism by which it protects against atherosclerosis, but more studies are needed to confirm this.
The addition of Path reduces daily insulin dosages, but study findings have not been consistent. Improvement of lipid profiles has also been weak with this combination therapy. Long-term studies are needed before any conclusions can be reached. Combination therapy should be primarily used for patients who achieve an insufficient reduction in blood sugar with insulin alone.
Q. Which is not safe in heart failure, Path or rosiglitazone?
Path & Rosiglitazone both belong to a class of antidiabetics called Thiazolidinediones. Rosiglitazone has been removed from the market because using this drug was associated with increased risk of cardiovascular events like heart attack and stroke. Path can cause heart failure too, but the risk is less that that with Rosiglitazone. Both the medicines should be avoided in heart failure.
Fortunately, there are many alternatives to Path- Metformin, Acarbose, Sitagliptin, Exenatide, Insulin or combination therapies of these medicines can be used.
Findings indicate that Path treatment is associated with a reduced dementia risk in Diabetes mellitus patients. Prospective studies are needed to evaluate a possible neuroprotective effect in these patients in an ageing population.
Path may be of use in infertile patients with polycystic ovary syndrome (PCOS) who are resistant to conventional ovulation induction such as by drugs like Clomiphene, Dexamethasone, or Metformin.
The use of Path for plaque psoriasis treatment is controversial. Some studies revealed no effect of Path 30 mg daily neither on the clinical response of moderate-to-severe psoriasis whereas others demonstrate that it could be considered as an efficacious and safe agent for the treatment of plaque psoriasis.
In a research study in a small number of autistic children, daily treatment with 30 or 60 mg Path for 3–4 months induced apparent clinical improvement. Path should be considered for further testing of therapeutic potential in autistic patients but as of now, autism is not an approved indication for Path use.
Path, either alone or as add-on therapy to conventional treatments, could clinically benefit patients of major depression according to a study.
A recent study shows that although Path causes a significant decrease in blood sugar, HbA1C and lipid levels, it is associated with weight gain, which would limit its utility. It has not been shown to cause weight loss.
Path has also been used to treat non-alcoholic steatohepatitis (fatty liver), but this use is presently considered experimental.
Path reduces recurrent stroke and major vascular events in stroke patients with insulin resistance, prediabetes, and diabetes mellitus. However, its use as a preventive therapy requires more research.
+more

User Submitted Feedback For Path 7.5mg Tablet

One of the following vendor pharmacies will deliver Path 7.5mg Tablet: PTS, OHM, HGI, SHP, BLP, RKS, MOM, SSA, NWP, GNC, LHA, DYG, EQN, OWP, ZVP, BIO, PLT, GTK, ATL, AGT, DEL, OIP, SHM, PSP, BSN, DDR, DLP, WSI, GTC, HEX, STA, GPT, SWA, PNT, RUS, AAR, MAX, AYU, NVL, OLT, SBL, BTM, SAT, MAK, SJP, RSS, EMB, PEN, RPP, KHH, IPL, ATP, RJH, HBV, NDP, JMJ, USF, HIP, DFP, JIV, FGH, SBA, MMS, ADT, 9T9, LCC, AAY, MPC, DPP

Substitutes for Path Tablet

Pioglit 7.5mg Tablet
Sun Pharmaceutical Industries Ltd
₹5.0/Tablet
5% costlier
Glitaris 7.5mg Tablet
Eris Life Sciences Pvt Ltd
₹5.45/Tablet
15% costlier
Pioglar 7.5mg Tablet
Sun Pharmaceutical Industries Ltd
₹6.05/Tablet
27% costlier
₹6.42/Tablet
35% costlier
Piopar 7.5mg Tablet
Mitoch Pharma Pvt Ltd
₹1.91/Tablet
save 60%
Top Diabetologists
doctor
Dr. Ambrish Mithal
MBBS, MD, DM
4.5
doctor
Dr. Rajiva Gupta
MBBS, Diploma, MD
4.2
doctor
Dr. Suman Kirti
MBBS, MD, Fellowship, Fellowship
4.3
doctor
4.2
doctor
4.8
cross img